OPKO Health, Inc. and Pfizer have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as growth failure in children who fail to show catch-up by 2 years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from one injection per day. Currently in a Phase III trial in adults and a Phase...